GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » Inventories, Raw Materials & Components

NovMetaPharma Co (XKRX:229500) Inventories, Raw Materials & Components : ₩1.64 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co Inventories, Raw Materials & Components?

NovMetaPharma Co's inventories, raw materials & components for the quarter that ended in Dec. 2023 was ₩1.64 Mil.

NovMetaPharma Co's quarterly raw materials stayed the same from Dec. 2021 (₩1.78 Mil) to Dec. 2022 (₩1.78 Mil) but then declined from Dec. 2022 (₩1.78 Mil) to Dec. 2023 (₩1.64 Mil).

NovMetaPharma Co's annual raw materials stayed the same from Dec. 2021 (₩1.78 Mil) to Dec. 2022 (₩1.78 Mil) but then declined from Dec. 2022 (₩1.78 Mil) to Dec. 2023 (₩1.64 Mil).


NovMetaPharma Co Inventories, Raw Materials & Components Historical Data

The historical data trend for NovMetaPharma Co's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co Inventories, Raw Materials & Components Chart

NovMetaPharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only - - 1.78 1.78 1.64

NovMetaPharma Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only - - 1.78 1.78 1.64

NovMetaPharma Co Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


NovMetaPharma Co Business Description

Industry
Traded in Other Exchanges
N/A
Address
727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co Headlines

No Headlines